Clinical trial
SPECTRA: Supraphysiological Androgen to Enhance Treatment Activity
NCT06039371 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SPECTRA: Supraphysiological Androgen to Enhance Treatment Activity
- Lead sponsor
- University of Washington
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 21, 2024
- Completion date
- November 1, 2028
- Enrollment
- 69 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma, stage ivb prostate cancer ajcc v8